TP53 and acute myeloid leukemia: Furthermore, VAFs of CALRK385fs47 (40.2%) and U2AF1Q157R (49.5%) mutations in the engrafted cells were the same as primary AML cells, while that of TP53 mutation increased to 99.9 from 37.4% in primary AML cells.